Danish biotech merger to attract major investors
Biotech companies Oncology Venture and Medical Prognosis Institute are planning a merger that will take the companies from the Swedish stock exchanges for growth companies to Stockholm's main market. "Investors and potential partners have expressed their desire for a one-stop-shop and this is what we comply with," says the CEO in both companies.
BY ALBERT RØNNING-ANDERSSON
When potential investors consider where to place their money, the biotech companies Oncology Venture and Medical Prognosis Institute are not the first choice.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Growing deficit in Oncology Venture
For abonnenter
Biotech company acquires former Novartis drug
For abonnenter
